Rationale: Given improvement in symptoms and lung function in people with cystic fibrosis (CF) taking elexacaftor/tezacaftor/ivacaftor (ETI), there is increasing interest in de-escalation of care although the effect on outcomes r... ...

请注册登录后继续浏览